logo ecco

logo ecco

Portal
  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • ECCO Code of Conduct
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter

ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster Presentations: Clinical: Therapy and Observation 2023

P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials

Ghosh, S.(1)*;Feagan, B.(2);Parra, R.S.(3);Lopes, S.(4);Steinlauf, A.(5);Kakuta, Y.(6);Joshi, N.(7);Lee, W.J.(7);Remple, V.(7);Lacerda, A.P.(7);Zhou, Q.(7);Xuan, S.(7);Louis, E.(8);

(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)Western University, n/a, London, Canada;(3)University of São Paulo, Ribeirão Preto Medical School, São Paulo, Brazil;(4)Centro Hospitalar e Universitário São João, n/a, Porto, Portugal;(5)Mount Sinai Hospital, IBD Clincal Center, New York, United States;(6)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan;(7)AbbVie Inc., n/a, Chicago, United States;(8)Centre Hospitalier Universitaire de Liège, Department of Gastroenterology, Liège, Belgium;

Background

Upadacitinib (UPA) demonstrated efficacy and safety in the phase 3 U-EXCEED (NCT03345836) and U-EXCEL (NCT03345849) induction, and U-ENDURE (NCT03345823) maintenance trials in patients (pts) with moderately to severely active Crohn’s disease (CD). We evaluated the impact of UPA on health-related quality of life (QoL) in pts with CD.

Methods

Clinical responders to UPA 45 mg (UPA45) in U-EXCEED and U-EXCEL induction trials were re-randomised at Week 12 (1:1:1) to UPA 15 mg (UPA15), UPA 30 mg (UPA30), or placebo (PBO) for 52 weeks of maintenance treatment in U-ENDURE; data from these induction and maintenance trials were included in this analysis. Endpoints included the percentage of pts who achieved an Inflammatory Bowel Disease Questionnaire (IBDQ) response (≥16 points), IBDQ remission (≥170 points), a meaningful within-person change (MWPC) from baseline of ≥9 points on the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), and of ≥4.1 and ≥3.9 points on the 36-item Short-Form Health Survey (SF-36) physical (PCS) and mental (MCS) component summary scores, respectively, at Weeks 4/12 of induction and Week 52 of maintenance. Adjusted risk differences compared to PBO, 95% confidence intervals, and p-values were calculated based on the Cochran-Mantel-Haenszel test.

Results

In U-EXCEED (n=324 UPA; 171 PBO) and U-EXCEL (n=350 UPA; 176 PBO), a greater proportion of UPA45- vs PBO-treated pts had an IBDQ response at Weeks 4 (U-EXCEED: 71.6% vs 47.6%; U-EXCEL: 71.0% vs 50.2%; p≤0.001) and 12 (U-EXCEED: 63.9% vs 44.4%; U-EXCEL: 68.4% vs 46.5%; p≤0.001; Figure 1). In UPA- vs PBO-treated pts, a greater proportion achieved IBDQ remission at Weeks 4 (U-EXCEED: 41.4% vs 22.4%; U-EXCEL: 44.2% vs 23.7%; p≤0.001) and 12 (all p≤0.001; Figure 1). At Week 12, a significantly greater proportion of UPA-treated pts vs PBO demonstrated a MWPC in FACIT-F, and SF-36 PCS and MCS from baseline (p≤0.001; Figure 1). Similar results for UPA45 vs PBO were achieved as early as Week 4 in FACIT-F (U-EXCEED: 42.3% vs 20.0%; U-EXCEL: 42.0% vs 27.0%), SF-36 PCS (U-EXCEED: 56.6% vs 37.2%; U-EXCEL: 53.0% vs 37.5%; p≤0.001) and MCS (p≤0.05). In the maintenance study U-ENDURE (n=168 UPA30; 169 UPA15; 165 PBO), a greater proportion of pts receiving UPA15 and UPA30 vs PBO achieved an IBDQ response (39.1%, 53.5% vs 20.4%), IBDQ remission (36.1%, 45.2% vs 13.5%), and a meaningful improvement from baseline in FACIT-F, SF-36 PCS and MCS through 52 weeks (p≤0.01; Figure 2).

Conclusion

In pts with moderately to severely active CD, UPA treatment significantly improved fatigue, disease-specific and generic QoL, compared with PBO, as early as Week 4 of induction. The effects were sustained through 52 weeks of maintenance treatment.




  • Posted in: Poster Presentations: Clinical: Therapy and Observation 2023
Logo_contact.png     T: +43 (0)1 710 22 42-0
F: +43 (0)1 710 22 42-001
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Home
  • Sitemap
  • Contact
  • Imprint
  • Data privacy statement
  • Media Policy

  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • ECCO Code of Conduct
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter